Benjamin Halladay - 14 Mar 2023 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role: Chief Financial Officer
Signature: /s/ Sheldon L. Koenig, by power of attorney
Issuer symbol: ESPR
Transactions as of: 14 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 15 Mar 2023, 09:21:21 UTC
Previous filing: 12 Dec 2022
Next filing: 15 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ESPR	Common Stock	Award	$0	+9,200	+14%	$0.000000	73,936	14 Mar 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ESPR	Stock Option (right to buy)	Award	$0	+39,000		$0.000000	39,000	14 Mar 2023	Common Stock	39,000	$4.02	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Such award will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service.
F2	Consists of 73,936 shares of common stock held, including 2,306 shares recently acquired in Esperion's Employee Stock Purchase Plan.
F3	Such options will vest over a four (4) year period in equal quarterly installments, the first of which shall be on June 15, 2023, subject to continued service.